Published in Mental Health Business Week, June 4th, 2005
The strengthened capital base, together with external grants, makes it possible for NsGene to initiate two planned clinical phase 1/2 Parkinson and Alzheimer studies within the coming 18 months and also to exploit new and promising findings within the company's gene discovery program.
In the near future, it is expected that clinical studies will be initiated with NsGene's nerve growth factor Neublastin for the treatment of neuropathic pain. Neublastin is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week